MTNB
- Matinas BioPharma Holdings, Inc.
()
Overview
Company Summary
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company that focuses on developing innovative therapeutics for various infectious diseases and conditions. They employ a proprietary lipid nano-crystal (LNC) platform technology to enhance the delivery and effectiveness of both small molecule and nucleic acid-based drugs.
Matinas BioPharma aims to address significant unmet medical needs by developing treatments that have potential advantages over existing therapies. They primarily target serious and drug-resistant infections, specifically focusing on addressing antifungal, antiviral, and antibacterial challenges.
Their lead product candidate is MAT2203, an orally-administered formulation of a broad-spectrum antifungal drug called amphotericin B. MAT2203 aims to offer an improved therapeutic option for patients affected by invasive fungal infections, which can be life-threatening, especially for individuals with compromised immune systems.
In addition to MAT2203, Matinas BioPharma has an extensive pipeline of preclinical and clinical product candidates. They have ongoing research and development efforts in developing antiviral therapies, such as a potential drug candidate for COVID-19. They also explore applications of their LNC platform in other therapeutic areas.
Overall, Matinas BioPharma is dedicated to pioneering innovative approaches to treat infectious diseases, enhance patient outcomes, and contribute to the advancement of healthcare.